EMMA (Emmaus Life Sciences) 3-Year Book Growth Rate: -9.60% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Emmaus Life Sciences 3-Year Book Growth Rate?

Emmaus Life Sciences EMMA +32.17% 3-Year Book Growth Rate is -9.60% as of Jun. 2026. The stock has 5 warning signs investors should review. Among 1,123 Biotechnology companies, Emmaus Life Sciences ranks worse than 51.02% on this metric.

Emmaus Life Sciences's Book Value per Share for the quarter that ended in Jun. 2026 was $-0.94.

During the past 3 years, the average Book Value per Share Growth Rate was -9.60% per year. During the past 5 years, the average Book Value per Share Growth Rate was -45.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Emmaus Life Sciences was 84.60% per year. The lowest was -484.50% per year. And the median was -26.70% per year.

Emmaus Life Sciences  (OTCPK:EMMA) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Emmaus Life Sciences 3-Year Book Growth Rate Related Terms

EMMA vs PCSA, LIMN, KAPA: 3-Year Book Growth Rate Comparison

For the Biotechnology subindustry, Emmaus Life Sciences's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emmaus Life Sciences 3-Year Book Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Emmaus Life Sciences's 3-Year Book Growth Rate falls into.


Emmaus Life Sciences 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

What does a 3-Year Book Growth Rate of -9.60% mean?
Emmaus Life Sciences (EMMA) has a 3-Year Book Growth Rate of -9.60% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Emmaus Life Sciences and its competitors. According to the industry distribution chart, Emmaus Life Sciences ranks #573 out of 1123 companies in the Biotechnology industry, placing it in the top 51%.
Is Emmaus Life Sciences' 3-Year Book Growth Rate too high?
Emmaus Life Sciences' current 3-Year Book Growth Rate is -9.60%. Based on the distribution chart, Emmaus Life Sciences ranks #573 out of 1123 companies in the Biotechnology industry, which is below the industry midpoint.
How does Emmaus Life Sciences' 3-Year Book Growth Rate compare to PCSA and LIMN?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #573 out of 1123 companies for 3-Year Book Growth Rate. This places Emmaus Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Emmaus Life Sciences and its competitors. Emmaus Life Sciences's current 3-Year Book Growth Rate is -9.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.07 — trading 582% above its estimated fair value. The current 3-Year Book Growth Rate is -9.60%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current 3-Year Book Growth Rate is -9.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emmaus Life Sciences Business Description

Address 21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.